Trial Profile
Efficacy and safety of tafamidis in patients with familial amyloid polyneuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy
- Focus Therapeutic Use
- 25 Nov 2015 New trial record
- 01 Jul 2011 Recruitment completed, according to results published in the European Journal of neurology.